The hypothesis of the existence of one or more schizophrenia susceptibility loci on chromosome 22q is supported by reports of genetic linkage and association, meta-analyses of linkage, and the observation of elevated risk for psychosis in people with velocardiofacial syndrome, caused by 22q11 microdeletions. We tested this hypothesis by evaluating 10 microsatellite markers spanning 22q in a multicenter sample of 779 pedigrees. We also incorporated age at onset and sex into the analysis as covariates. No significant evidence for linkage to schizophrenia or for linkage associated with earlier age at onset, gender, or heterogeneity across sites was observed. We interpret these findings to mean that the population-wide effects of putative 22q schizophrenia susceptibility loci are too weak to detect with linkage analysis even in large samples.
Introduction
Schizophrenia is a severe, debilitating disorder characterized by delusional beliefs, hallucinations, disordered speech, and deficits in emotional and social behavior. It is strongly familial, but the pattern of inheritance is complex, with most data favoring the interaction of multiple genes, each exerting a small to moderate effect on overall disease risk. There are now a number of candidate genomic regions supported by converging evidence from independent studies. 1, 2 One of these is a broad region of chromosome 22q.
Pulver et al 3 reported a maximum LOD score (MLS) of 1.54 at IL2RB in 39 multiplex European-American pedigrees. There have been other positive reports, including some in partially or completely overlapping multicenter samples, and these are summarized in Table 1 . Most of these findings have focused on two regions: 22q12, in the vicinity of D22S278, and 22q11, closer to the microdeletion responsible for the velocardiofacial syndrome (VCFS). No study has produced genome-wide statistically significant results in these regions, and the most positive linkage report in a single sample (max LOD ¼ 3.8) is in 22q13 for bipolar disorder. 21 Badner and Gershon 1 carried out a meta-analysis of published schizophrenia and bipolar genome scan data using Multiple Scan Probability, which combines Pvalues from linkage regions with clusters of positive results. At 32 cM on the Marshfield map, approximately 2 Mb centromeric to D22S278, they reported evidence for linkage to schizophrenia (P ¼ 0.0002), and stronger evidence for linkage to bipolar disorder (P ¼ 0.00003). Lewis et al 2 reported on a rank-based Genome Scan Meta-Analysis method, 22 which considers all available (published and unpublished) genome scan data for the schizophrenia phenotype (approximately 1200 pedigrees), including most although not all of the samples shown in the table. Chromosome 22 did not produce one of the five most positive linkage results in any of the 20 scans, yet many scans produced small positive scores on proximal 22q, and the 30 cM proximal 22q region, which includes the VCFS region, produced the eighth-best rank in the genome. This was one of 12 Â 30 cM 'bins' in 10 chromosomal regions that met aggregate criteria for significance, more often than expected by chance (ie clusters of nominally significant P-values that did not occur in 1000 replicates of the entire unlinked data set). A companion analysis of all available bipolar disorder data did not produce a significant result. 23 The authors concluded that many or all of these regions, including chromosome 22q, were likely to contain weakly linked schizophrenia susceptibility loci.
Chromosome 22q has been of particular interest because schizophrenia or schizoaffective disorder is observed in over 20% of patients with VCFS, 14, 24 which is caused by 1.5-3 Mb microdeletions in 22q11. VCFS is characterized by cleft palate, cardiac defects, learning disabilities and a typical facial appearance. 25 Psychosis is associated with a variable deletion size (1.5-3.0 Mb), 26 and may occur in the absence of cardiac defects and cleft palate. 27, 28 VCFS microdeletions have been found in 0.6% 29 to 2% 30 of adult patients with schizophrenia and 6% of those in whom onset was below the age of 16 years. 31 Thus, it appears highly likely that deletion of one or more 22q11 genes can produce a schizophrenia-like phenotype. It is less clear whether sequence variations in any of these genes can also increase risk for schizophrenia in individuals without microdeletions. It is possible that one or more genes on 22q11 will be associated with an early-onset phenotype, given the higher 22q11 microdeletion rate in children with schizophrenia, and the multiple premorbid cognitive and social impairments and distinguishing MRI features of children with VCFS and schizophrenia. 31 Evidence for association with schizophrenia has recently been reported for several 22q loci as shown in 37 Two groups have reported evidence for association between a microsatellite marker in the VCFS deletion region, D22S944, and schizophrenia. 38, 39 Analyses of small samples of parent-proband trios 40 or cases and controls 41 showed no linkage disequilibrium between D22S278 and schizophrenia after correction for multiple tests. The strongest findings on 22q thus far are those for PRODH and COMT, although the PRODH finding was not confirmed in a recent study. 42 Distal to the microdeletion region, weak association to schizophrenia was reported for a VNTR in the 5 0 -untranslated region of YWHAH (tyrosine-3-monooxygenase, 14-3-3 protein eta gene, 22q12.3). 43 Also, in a microarray study of 300 candidate genes in three independent brain sample cohorts, significant upregulation of gene expression in schizophrenia was reported for APOL1 (apolipoprotein L1, 22q13.1), APOL2 (apolipoprotein L2, 22q12) and APOL4 (apolipoprotein L4, 22q13.1). 44 Owing to these reports of linkage, and association between schizophrenia and diverse loci on chromosome 22q and of expression of genes on 22q in the brains of people with schizophrenia, we carried out a linkage study of 10 microsatellite markers covering all of 22q in a large multicenter schizophrenia pedigree sample, and incorporated both age at onset (AAO) and sex into the analysis as covariates. As noted in Table 1 , the clinical sample overlapped partially with several previous multicenter analyses; however, these were limited to a few markers near IL2RB or D22S278. Linkage has not been previously analyzed in a large multicenter sample using markers spanning all of chromosome 22q.
Materials and methods

Clinical sample
The sample is summarized in Table 3 and has been described previously. 45 Briefly, clinical samples collected by eight research groups (the seven participating collaborators plus the NIMH Human Genetics Initiative sample) have been combined into a sample of 779 informative pedigrees (679 of them of predominantly European ancestry) containing 838 independent affected sib pairs and 1918 genotyped individuals with schizophrenia or schizoaffective disorder. Each sample was collected with appropriate human subjects approvals including informed consent. Subjects were interviewed by research clinicians using standardized diagnostic instruments, and bestestimate diagnoses were carried out based on interviews, medical records, and family informant reports. A case was considered affected if the DSM-IIIR diagnosis was schizophrenia or schizoaffective disorder. Predominant ethnic origins across the sample 
Markers and genotyping
The 10 microsatellite markers are listed in Table 4 . Eight are from the Applied Biosystems (Foster City, CA, USA) HD5 map, and two additional markers are within the VCFS microdeletion region (D22S1638, D22S941), and had been previously successfully typed by the Cardiff group. Fluoresceinated primers were synthesized by ABI and distributed to each lab. Each group genotyped its own samples except that the AUS/US, JHU, and NIMH samples were genotyped by the Australian Genome Research Facility. The standard semiautomated genotyping methods used by each group have been described in the references listed in Table 1 . The markers covered 60.8 cM of sexaveraged genetic distance, with an average marker spacing of 6.76 cM and average marker heterozygosity of 0.76. Marker allele frequencies were determined for each data set, and each analysis was set up so that the allele frequencies assumed for each pedigree were those computed for its data set.
Statistical analyses
Planned primary analyses were multipoint affected sibling pair (ASP) analysis using the possible triangle algorithm and yielding MLS, 59 and multipoint nonparametric linkage (NPL) scores (Z ALL ). 60 In addition, logistic regression analysis 61 was used to test for intersample heterogeneity of ASP sharing, for overall significance of linkage allowing for this heterogeneity, and for linkage while accounting for covariates as described below. Unless otherwise noted, P-values are regional values determined empirically by simulating 5000 replicates of the sample with no linkage present.
Additional multipoint analyses of identity-bydescent (IBD) sharing in ASPs were carried out to test the effect of age at onset (of psychosis) and sex as covariates. The IBD sharing probability for each ASP was modeled as a logistic regression on the observed covariates, as suggested by Rice, 62 enabling likelihood-ratio tests of the effect of each covariate on the IBD sharing probability to be tested. Note that these analyses produced slightly different results than the possible triangle algorithm discussed above, even without covariates, in part because ASPs were omitted if AAO was not known for either sib, and in part because a multiplicative model for IBD is applied, where the probabilities of an ASP sharing 0, 1, or 2 alleles IBD, respectively, are assumed to be (1-p) 2 , 2p(1-p), and p 2 , and the likelihood is then maximized with respect to p such that PX0.5.
The following covariates were used in the analyses: (1) the mean age-at-onset of the two sibs (AAO-Mean); (2) the absolute value of the difference in ages at onset (AAO-Diff); and (3) sex (coded as a factor with three levels corresponding to M-M, M-F, or F-F pairs). The effects of AAO-Mean and AAO-Diff were then evaluated while allowing for sex effects, by fitting both variables simultaneously (Mean þ Sex, Diff þ Sex). Models containing main effects and interactions between AAO and Sex were also fitted. Regionwide P-values, the probability of observing a 'LOD score anywhere in the region being tested' greater than the observed LOD score, were estimated by randomly permuting covariates among the affected sib pairs. Note that all of the MLS results for logistic regression with covariates are associated with large numbers of degrees of freedom, so that thresholds for genome-wide significance are quite high and are not approached here, even where scores are above 4 or even 5. Table 5 and Figures 1 and 2 show results for multipoint ASP and NPL analyses for each sample and for the entire data set. For the entire data set, there were no statistically significant linkage findings for either analysis, with a peak MLS ¼ 0.97 (60.8 cM, P ¼ 0.19) and a peak NPL ¼ 1.39 (60.8 cM, P ¼ 0.066). Although results varied across the samples, there was no statistically significant evidence for intersample heterogeneity. The overall MLS for IBD sharing in ASPs allowing for heterogeneity was 3.28 (60.8 cM, P ¼ 0.057). Nominally significant MLS results were observed in the Chicago and JHU samples, on distal and proximal 22q, respectively, and nominally significant NPL results were observed in the AUS/US and NIMH samples, with a trend (P ¼ 0.06) in the JHU sample, at three different locations. In the logistic regression analysis without covariates, nominally significant results were observed in the Chicago, JHU, and NIMH samples, with a trend (P ¼ 0.051) in the Cardiff sample. Table 6 shows peak MLS results and their locations for each sample and the combined sample. As a whole, the sample showed no AAO or gender effect. All observed relationships between AAO and IBD were in the opposite direction to the predicted one, that is, older AAO predicted increased IBD sharing in the AUS/US and Chicago samples. In two samples (but not the entire sample), there were interactions between sex and increased AAO-Mean in predicting IBD. In one of these (NIMH), this interaction was observed in very proximal 22q (2.1 cM) near the VCFS region. 
Results
Multipoint ASP and NPL analyses
AAO and sex effects
Parent-of-origin effects
To follow up DeLisi et al's 13 report of excess (paternal/ maternal) sharing, we tested for differences between the IBD probabilities of paternally and maternally inherited alleles in our affected sib pairs. This was done by modeling the IBD probabilities of the paternal and maternal alleles as logistic regressions with the same intercept, but including a parameter in the regression of maternal IBD to reflect a difference in the IBD probabilities (ie a parent-of-origin effect). The significance of the parent-of-origin effect was assessed by randomly permuting parental genotypes within sibships, maximizing the LOD score allowing for a parentof-origin effect, and comparing the maximized LOD score to that obtained from the actual data. No significant results were obtained either when the parent-oforigin effect was assumed constant across the combined sample or when it was allowed to differ between groups. Groups were also analyzed individually, but none exhibited a significant parent-of-origin effect.
Discussion
In our large collaborative sample, we found no statistically significant linkage findings across our entire data set, for MLS, NPL, or logistic regression analyses. Nominally significant results were observed in some samples, but these were in diverse locations. Therefore, even with this large multicenter sample, we have been unable to use linkage analysis to clarify whether and where there are genes on chromosome 22q that influence susceptibility to schizophrenia in individuals without VCFS microdeletions. Age at onset and sex were taken into account in these analyses, because of reports that these factors mediated association to schizophrenia of two genes in the VCFS region, PRODH (AAO) and COMT (sex). These covariates did not have a significant effect on this multicenter sample, and nominally significant effects were observed in only a few samples at diverse locations, with all AAO effects in the direction opposite to that predicted (increased rather than decreased AAO predicting increased IBD).
Weakly significant P-values
It may be helpful to discuss briefly the interpretation of weakly significant P-values. In this field, there is a need to prevent false discoveries through the application of sufficiently stringent criteria for significance, 71 ,72 while at the same time avoiding the risk MLS ¼ maximum LOD score for IBD sharing among affected sibling pairs in logistic regression analysis (considering only pairs where age at onset was known for both cases). There was also a significant interaction between increasing AAO and Sex effects (P ¼ 0.014, by w 2 approximation with 2 df). d P ¼ 0.043 for increase in MLS for AAO-Mean vs no covar (greater AAO predicting increased IBD sharing). e P ¼ 0.017 for increase in MLS for Mean þ Sex vs Sex. f P ¼ 0.011 for interaction between increasing AAO-Mean and Sex effects (by w 2 approximation with 2 df).
that true effects are missed; the latter is an important consideration particularly when the effect of each gene might be expected to be small and thus the power of linkage studies even of this scale is limited; this is probably particularly true for follow-up (replication) studies such as ours, which are likely to yield smaller (and truer) effect sizes than the original report. 73 Some investigators have recently encouraged optimizing procedures for controlling and eliminating false discoveries, thereby achieving an acceptable ratio of true and false discoveries. 74 One interpretation of our weakly significant P-values is that these results most likely reflect considerable disease heterogeneity in our sample and in these populations more generally.
The phenotype used in these analyses, DSM-IIIR schizophrenia and schizoaffective disorder, is consistent with other current schizophrenia linkage and association studies, but it is possible that a different definition of the phenotype would be more strongly linked to one or more chromosome 22q loci. The ethnicity of the samples could also be an issue, in that about 13% of the pedigrees were not of European ancestry. Evidence for linkage or association to schizophrenia on chromosome 22q has been previously observed in some ethnically diverse samples. 13, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [59] [60] [61] [62] The most parsimonious explanations of these results would be either that there are no schizophrenia susceptibility loci on chromosome 22q or that their population-wide effects are sufficiently weak that they cannot be reliably detected by linkage methods with our sample size. We would tentatively favor the second hypothesis, for two reasons:
(1) Evidence for schizophrenia linkage on proximal 22q was observed in two meta-analyses of schizophrenia genome scans, as discussed in the introduction. The larger of these analyses considered about 1200 pedigrees, of which about 500 were included here (parts of the AUS/US, Bonn, Cardiff, JHU, NIMH and VCU/IRE samples). The rank-based method used in this analysis can detect 'aggregate' evidence for linkage (nominally significant results by two empirical criteria in more bins than expected by chance) even when the actual combined linkage scores do not reach genome-wide significance, that is, it is more powerful than a combined linkage analysis but localizes the result only to broad bins. 75 It is not known how either meta-analysis method is affected by multiple weakly linked loci in the same region (perhaps affecting different overlapping sets of families). Given the meta-analysis results, it is quite possible that one or more susceptibility loci exist on 22q but cannot be detected by linkage methods in our sample. The sporadic evidence for linkage in individual samples could reflect the variable locations of weak linkage peaks that can be observed in samples with inadequate power to detect them reliably. 76, 77 (2) Both the relationship between VCFS and schizophrenia, and the evidence for association with schizophrenia reported for loci such as COMT, suggest that there are one or more susceptibility loci on 22q that underlie the meta-analysis linkage result. If this is the case, then it is likely that their population-wide effects are too weak to be reliably detected by linkage methods even in rather large samples.
Limitations
Although greater power is achieved by collaborative pooling of data sets, there are a number of limitations associated with this type of study:
(a) There may be undetected differences across samples, which obscures linkage. For example, there could be undetected intersite differences in sampling frames and diagnostic approaches despite the fact that each group uses internationally accepted diagnostic criteria. (b) The ethnicity of the study population across diverse samples has a greater potential for variation, which could result in locus heterogeneity at certain susceptibility loci (although the vast majority of families studied here are of predominantly European ancestry can never rule out false-negative findings; indeed, we assume that there are one or more genes on chromosome 22q that can influence psychosis vulnerability, given the prevalence of psychosis in VCFS patients, but we and others have not been able to detect these loci using genetic linkage methods.
Suggestions
A number of suggestions with regard to multicenter follow-up studies may be helpful:
(a) In the composition of the collaborative group, it is important to avoid preferential selection bias for groups with positive findings. For example, we formed our multicenter sample 5 years ago and have kept it constant regardless of the region being tested (except for permitting individual groups to add newly available families for whom linkage results in new regions of interest were not known). (b) In the case of findings that clearly originated in one or two of the samples that are included in the multicenter analysis, it can be useful to agree in advance upon a differentiation between the 'new' families and the 'old' families associated with the original positive evidence for linkage. However, for some findings, the pattern of previous results will not permit such a clear differentiation, as was the case here where none of the samples had produced previous suggestive or significant evidence for linkage on chromosome 22q. (c) A common set of markers should be genotyped in all samples, with adequate coverage of the broad region that produced evidence for linkage in other studies, and with as dense a map as is feasible to maximize linkage information. The markers that produced evidence for linkage in the original study should generally be included, although sometimes there is subsequent evidence that other nearby markers perform better and are more informative. (d) It may be useful to carry out linkage analyses such that linkage scores for each sample are computed using its own marker allele frequencies (as was done here). On the other hand, we have not observed significant allele frequency differences among our samples. If a somewhat larger and more ethnically heterogeneous multicenter study were attempted, it would be possible to use raw allele sizes (whether from one central genotyping lab, or using a set of common controls to standardize sizes across labs) to study population substructure directly, and then either to subdivide the sample for linkage analysis or to enter the structured groupings into an analysis (such as logistic regression analysis) as covariates. (e) Analyses are needed to model and systematically test differences between centers; for example, in this and previous studies, we have used logistic regression of IBD allele sharing of ASPs using site as a covariate 62 to evaluate: (i) the significance of difference in sharing proportions among sites (ie test for intersite heterogeneity) and (ii) the overall significance of linkage while testing for intersite heterogeneity. (f) We make the assumption, based on our many experiences with crosssite collaboration, that there are undetected but systematic differences in the ways that standard criteria for the diagnosis of schizophrenia are applied across research groupsfor example, each group is likely to develop a degree of internal consistency in determining when to exclude a subject for excessive substance abuse or when to consider affective features to be predominant. It might be therefore useful to introduce a more dimensional approach to the rating of symptoms and symptom clusters [79] [80] [81] in order to describe phenotypic subgroups for linkage analysis. We are planning to attempt this type of crosssample dimensional strategy in future studies.
Conclusion
Linkage analysis of 10 chromosome 22q microsatellite markers in a large multicenter sample failed to produce significant evidence for linkage to schizophrenia or for linkage associated with earlier age at onset, the sex of the ASPs, or heterogeneity across sites. Slightly positive evidence for linkage was observed on distal 22q for the entire sample, with P ¼ 0.057 in a logistic regression analysis of IBD sharing in ASPs while taking intersite heterogeneity into account, and P ¼ 0.066 in an NPL analysis. While it is possible that there are no schizophrenia susceptibility loci on 22q, evidence from meta-analyses of schizophrenia genome scan data and several reports of association to specific genes all suggest that there may, indeed, be such loci, but that their populationwide effects are too weak to detect with linkage analysis even in a rather large sample.
